Please login to the form below

Not currently logged in
Email:
Password:

Targovax appoints Michael Bogenstaetter as chief business officer

He joins the immuno-oncology biotech from Interim Assignments

Michael BogenstaetterNorwegian biotechTargovax has appointed its new chief business officer in the form of Michael Bogenstaetter, who joins following 25 years’ experience in the biotech and pharmaceutical industries.

Bogenstaetter previously served as an advisor of life sciences and health care at Interim Assignments, and before that he served as global head strategy, project management and operations drug discovery at Sanofi.

He has also held numerous roles for Novartis, MSD and Johnson and Johnson.

Øystein Soug, chief executive officer of Targovax, said: “Bogenstaetter’s extensive experience of business development and corporate strategy in the biotech and pharma industry will be indispensable to us.”

22nd January 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...